Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma

Takafumi Shichijo1 | Dai Maruyama1 | Nobuhiko Yamauchi2
Akiko Miyagi Maeshima3 | Masato Sugano4 | Sayako Yuda1 | Kinuko Tajima1
Hiroaki Kurihara5 | Kaoru Shimada6 | Tomotaka Suzuki1 | Kosuke Toyoda1
Shinichi Makita1 | Suguru Fukuhara1 | Wataru Munakata1 | Tatsuya Suzuki1
Yukio Kobayashi1 | Hirokazu Taniguchi3 | Yosuke Minami2 | Koji Izutsu1
Kensei Tobinai1

1Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
2Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan
3Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
4Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan
5Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan
6Department of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Japan

Correspondence
Dai Maruyama, Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Email: dmaruyam@ncc.go.jp

Abstract
Although histologic analysis is the gold standard for diagnosing follicular lymphoma (FL) transformation, many patients are diagnosed with transformation by clinical factors as biopsy specimens often cannot be obtained. Despite the frequency of clinical diagnosis, no clinical assessment tool has yet been established for FL transformation in the rituximab era. We derived and validated a transformation scoring system (TSS) based on retrospective analyses of 126 patients with biopsy-proven FL and histologic transformation (HT) at two hospitals of the National Cancer Center of Japan. In the derivation set (76 patients), the detailed analyses of the clinical characteristics at disease progression showed that lactate dehydrogenase (LDH) elevation, focal lymph nodal (LN) enlargement, hemoglobin <12 g/dl, and poor performance status (PS) (2-4) were associated with HT. The weights of these variables were decided based on the regression coefficients. Next, we constructed a TSS encompassing the above four factors: LDH, (> upper limit of normal [ULN], ≤ULN ×2) (1 point), (≥ULN ×2) (2 points); focal LN enlargement, (≥3 cm, <7 cm) (1 point), (≥7 cm) (2 points); hemoglobin <12 g/dl (1 point); poor PS (2 points). We identified a high positive predictive value (PPV) (96.4%) and negative predictive value (NPV) (85.4%) for diagnosing HT when a cutoff score of 2 was selected for our TSS. In an external validation set (50 patients), the probability of HT was high with scores ≥2 (PPV, 93.3%; NPV, 82.9%). We developed a TSS that offers a simple, yet, valuable tool, for diagnosing HT, especially in patients who cannot undergo biopsy.

KEYWORDS
clinical transformation, diffuse large B-cell lymphoma, follicular lymphoma, histologic transformation, scoring system
Follicular lymphoma (FL) is a major type of indolent B-cell lymphoma. The watch and wait strategy remains an acceptable approach for FL patients, especially for those with low tumor burden, even in the rituximab era.\(^1\)\(^-\)\(^5\) Although FL remains an incurable disease, clinical outcomes, even in patients with high tumor burden, have improved, mainly owing to chemoimmunotherapy.\(^1\)\(^,\)\(^2\)\(^-\)\(^6\)\(^-\)\(^13\)

However, histologic transformation (HT) is a critical event because the prognosis of FL patients with HT is poorer than that of FL patients without HT; this has remained true even after the introduction of rituximab.\(^14\)\(^-\)\(^21\) Several studies have reported that transformation from FL to aggressive lymphoma occurs in 4\%–22\% of the patients within 5 years from the initial diagnosis.\(^15\)\(^-\)\(^18\)\(^,\)\(^20\)\(^-\)\(^26\) The probability of transformation varies among these studies owing to the heterogeneity in study designs, such as the inclusion criteria of patients (especially if those with clinical transformation were included\(^20\)\(^,\)\(^22\)\(^,\)\(^24\)\(^,\)\(^26\) or excluded\(^16\)\(^-\)\(^18\)\(^,\)\(^21\)\(^,\)\(^23\)\(^,\)\(^25\) ), the years when the studies were conducted (in the pre-rituximab era\(^22\)\(^-\)\(^25\) or in the rituximab era\(^15\)\(^-\)\(^18\)\(^,\)\(^20\)\(^,\)\(^21\)\(^,\)\(^26\) ), and the definition of transformation.

Although histologic confirmation by biopsy is the gold standard for diagnosing transformation,\(^27\) it is not always possible to obtain the specimen for biopsy (e.g., in cases when disease progression is in an inaccessible location or develops very rapidly). Of note, even in prospective studies,\(^16\)\(^,\)\(^21\)\(^,\)\(^28\) the specimen for biopsy could not be obtained in 60\%–80\% of the patients at the time of disease progression. Moreover, a previous study has reported that more than half of the FL patients with transformation were diagnosed based only on clinical criteria and at the physician’s discretion without a histologic confirmation.\(^15\) Moreover, limited information is available regarding the clinical factors at the time of disease progression that are associated with the transformation.\(^17\)\(^,\)\(^18\)\(^,\)\(^23\)\(^,\)\(^24\) Although the clinical criteria for transformation had been proposed in the pre-rituximab era,\(^24\) a recent retrospective study indicated that such criteria may not be reliably accepted in the rituximab era.\(^18\) Moreover, to the best of our knowledge, no study has been conducted in the rituximab era to compare and statistically identify the clinical factors associated with disease progression in patients with biopsy-proven FL and HT.

Therefore, the present study conducted a retrospective analysis at two hospitals of the National Cancer Center of Japan to develop a transformation scoring system (TSS) for the diagnosis of the clinical transformation of FL that would be easy to use in both daily practice and clinical trials.
compared using the log-rank test. The OS from disease progression was defined as the duration from disease progression to death from any cause or the date of the last follow-up. The cumulative incidence of HT was calculated using the Gray's method. In a competing risk model for HT, death before HT was defined as a competing risk. The time to HT was calculated as the duration between the date of initial diagnosis of FL and the occurrence of HT. Clinical data for each patient were extracted from the patient's medical records. A two-sided $p$-value <0.05 was considered statistically significant. Variables significantly associated with HT in univariate analysis were included in the multivariate logistic regression model. Clinical stage was determined according to the Ann Arbor classification system. Focal lymph nodal (LN) enlargement was defined when the nodal mass larger than 3 cm was observed in only one nodal area and the size of nodal masses in other nodal areas was less than 3 cm. The nodal area was defined according to the Follicular Lymphoma International Prognostic Index (FLIPI)\textsuperscript{31}. Focal LN enlargement was also assessed for larger diameter (the nodal mass $\geq$ 7 cm). Bulky disease was defined as the nodal mass $\geq$ 6 cm in diameter, regardless of the number of nodal areas. The maximum standardized uptake value (SUVmax) was assessed for patients who received $^{18}$F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). The TSS scores were calculated from a regression coefficient for each statistically significant variable. Receiver operating characteristic (ROC) curve analysis was used to assess the accuracy of the TSS and SUVmax, the cutoff values for which were determined with a high positive predictive value (PPV) and negative predictive value (NPV). Statistical analyses were performed using the EZR software package, version 1.32 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 3.2.4).\textsuperscript{32}

3 | RESULTS

3.1 | Development of the transformation scoring system in the derivation set

Patients’ selection flowcharts are shown in Figure 1A-B. During the study period in the NCCH cohort, 459 patients were diagnosed with FL (grades 1, 2, or 3a) at the NCCH (Figure 1A). The median duration of follow-up among these patients was 7.1 (range: 0.2-16.6) years. Disease progression was observed in 184 patients, among whom 80 (43%) had the histologic documentation (FL in 42, HT with DLBCL in 34, and HT other than DLBCL in 4). Finally, we identified 76 patients with biopsy-proven FL or HT with DLBCL as subjects for the derivation analysis. In this cohort, the first-line treatment between FL and HT was similar; 22 patients (28.9%; FL in 11 and HT in 11) were initially managed with WW, 45 patients (59.2%, FL in 24 and HT in 21) were immediately treated with rituximab-containing therapy, and nine patients (11.8%, FL in 7 and HT in 2) were immediately treated with local radiotherapy. Further, both groups had similarly received R-CHOP therapy before disease progression (FL in 20 and HT in 20).

The clinical characteristics of 76 patients with biopsy-proven FL or HT at the time of disease progression are shown in Table 1. The median age was 61.5 years (range, 32-85 years). On univariate analysis, B symptoms, poor Eastern Cooperative Oncology Group performance status (PS) score (2-4), lactate dehydrogenase (LDH) level over

![Figure 1](image-url) Flowcharts for patients’ selection The NCCH cohort (A) and the NCCHE cohort (B). Abbreviations: NCCH, National Cancer Center Hospital; NCCHE, National Cancer Center Hospital-East; FL, follicular lymphoma; BL, Burkitt lymphoma; HL, Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma.
| Characteristics | Total (N = 76) | FL (n = 42) | HT (n = 34) | p-value<sup>a</sup> |
|-----------------|---------------|-------------|-------------|---------------------|
| **Age**         |               |             |             |                     |
| Median (range), years | 61.5 (32-85) | 62.5 (36-85) | 61.5 (31-83) | 0.493              |
| <61             | 33            | 17          | 16          | 0.644              |
| ≥61             | 43            | 25          | 18          |                     |
| **Sex**         |               |             |             |                     |
| Female          | 38            | 17          | 21          | 0.106              |
| Male            | 38            | 25          | 13          |                     |
| **B symptoms**  |               |             |             |                     |
| No              | 65            | 39          | 26          | 0.003              |
| Yes             | 7             | 0           | 7           | 20.6               |
| Missing         | 4             | 3           | 1           | 2.9                |
| **ECOG performance status** | | | | |
| 0-1             | 65            | 40          | 25          | 0.001              |
| 2-4             | 8             | 0           | 8           | 23.5               |
| Missing         | 3             | 2           | 1           | 2.9                |
| **Ann Arbor Stage** | | | | |
| I-II            | 19            | 11          | 8           | 0.585              |
| III-IV          | 45            | 21          | 24          | 0.706              |
| Missing         | 12            | 10          | 2           |                     |
| **LDH**         |               |             |             | <0.001             |
| Median (range), IU/L | 197 (116-5540) | 176.5 (116-288) | 276.5 (143-5540) |              |
| ≤ULN            | 46            | 35          | 11          | <0.001             |
| >ULN            | 30            | 7           | 23          | 67.6               |
| ≤ULN ×2         | 67            | 42          | 25          | <0.001             |
| >ULN ×2         | 9             | 0           | 9           | 26.5               |
| **Hemoglobin**  |               |             |             |                     |
| Median (range), g/dl | 12.85 (4-17.4) | 13.15 (9.8-17.4) | 12.55 (4-15.2) | 0.011              |
| <12             | 20            | 6           | 14          | 41.2               |
| ≥12             | 56            | 36          | 20          | 58.8               |
| **White blood cell count** | | | | |
| Median (range), /μl | 5100 (800-40200) | 5100 (2900-40200) | 5050 (800-31000) | 0.415             |
| **Platelet count** | | | | |
| Median (range), ×10^4 /μl | 17.8 (0.3-51.1) | 18.15 (8.9-39.8) | 17.55 (0.3-51.1) | 0.758             |
| **Hypercalcemia** | | | | |
| Median (range), mg/dl | 9.4 (7.7-12) | 9.4 (8.510.3) | 9.4 (7.7-12) | 0.806              |
| No              | 74            | 42          | 32          |                     |
| Yes             | 2             | 0           | 2           | 5.9                |
| **CRP**         |               |             |             | <0.001             |
| Median (range), mg/dl | 0.155 (0.02-26.9) | 0.1 (0.02-4.34) | 0.705 (0.02-26.9) |              |
| ≤ULN            | 36            | 25          | 11          | 32.4               |
| >ULN            | 40            | 17          | 23          | 67.6               |
| **Bone marrow involvement** | | | | |
| Negative        | 41            | 22          | 19          | 0.355              |

(Continues)
| Characteristics | Total (N = 76) | FL (n = 42) | HT (n = 34) | p-value* |
|-----------------|--------------|------------|------------|----------|
|                 | No. | %  | No. | %  | No. | %  |        |          |
| Positive        | 14  | 18.4 | 5   | 11.9 | 9   | 26.5 |
| Missing         | 21  | 27.6 | 15  | 35.7 | 6   | 17.6 |
| Extranodal site, excluding BM |        |          |        |        |        |        |
| Negative        | 50  | 65.8 | 31  | 73.8 | 19  | 55.9 | 0.080 |
| Positive        | 24  | 31.6 | 9   | 21.4 | 15  | 44.1 |
| Missing         | 2   | 2.6  | 2   | 4.8  | 0   | 0.0  |
| Bulky disease   |        |          |        |        |        |          |
| Median (range), cm | 3.3 (0-12.1) | 2.8 (0-8.2) | 5.6 (0-12.1) | <0.001 |
| <6 cm            | 57  | 75.0 | 39  | 92.9 | 18  | 52.9 |
| ≥6 cm            | 18  | 23.7 | 2   | 4.8  | 16  | 47.1 |
| Missing          | 1   | 1.3  | 1   | 2.4  | 0   | 0.0  |
| Focal lymph nodal enlargement |        |          |        |        |        |          |
| No^b             | 47  | 61.8 | 33  | 78.6 | 14  | 41.2 | 0.001 |
| Yes (≥3 cm)^c    | 27  | 35.5 | 8   | 19.0 | 19  | 55.9 |
| No^d             | 64  | 84.2 | 41  | 97.6 | 23  | 67.6 | <0.001 |
| Yes (≥7 cm)^e    | 10  | 13.2 | 0   | 0.0  | 10  | 29.4 |
| Missing          | 2   | 2.6  | 1   | 2.4  | 1   | 2.9  |
| SUVmax           |        |          |        |        |        |          |
| Median (range)   | 11.63 (2.11-33.34) | 9.20 (2.11-16.7) | 16.74 (4.86-33.34) | <0.001 |
| Missing          | 26  | 34.2 | 14  | 33.3 | 12  | 35.3 |
| FDG-PET/CT       | 50  | 65.8 | 28  | 66.7 | 22  | 64.7 |
| SUVmax <10       | 19  | 38.0 | 16  | 57.0 | 3   | 13.6 | 0.003 |
| SUVmax ≥10       | 31  | 62.0 | 12  | 43.0 | 19  | 86.4 |
| SUVmax <16       | 36  | 72.0 | 27  | 96.4 | 9   | 40.9 | <0.001 |
| SUVmax ≥16       | 14  | 28.0 | 1   | 3.6  | 13  | 59.1 |
| SUVmax <20       | 45  | 90.0 | 28  | 100.0 | 17  | 77.3 | 0.012 |
| SUVmax ≥20       | 5   | 10.0 | 0   | 0.0  | 5   | 22.7 |
| FLIPI            |        |          |        |        |        |          |
| Low risk         | 26  | 34.2 | 14  | 42.9 | 8   | 23.5 | 0.046 |
| Intermediate risk| 19  | 25.0 | 11  | 26.2 | 8   | 23.5 |
| Poor risk        | 28  | 36.8 | 10  | 23.8 | 18  | 52.9 |
| Missing          | 3   | 3.9  | 2   | 4.8  | 1   | 2.9 |
| IPI              |        |          |        |        |        |          |
| Low risk         | 27  | 35.5 | 19  | 45.2 | 8   | 23.5 | <0.001 |
| Low-intermediate risk | 27  | 35.5 | 18  | 42.9 | 9   | 26.5 |
| High-intermediate risk | 12  | 15.8 | 3   | 7.1  | 9   | 26.5 |
| High risk        | 7   | 9.2  | 0   | 0.0  | 7   | 20.6 |
| Missing          | 3   | 3.9  | 2   | 4.8  | 1   | 2.9 |

Number of relapses from initial diagnosis

|        |        |
|--------|--------|
| 1      | 53     |
| ≥2     | 23     |

Abbreviations: BM, bone marrow; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; FDG-PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography; FLIPI, Follicular Lymphoma International Prognostic Index; IPI, Internal Prognostic Index; LDH, lactate dehydrogenase; SUVmax, maximum standardized uptake value; ULN, upper limit of normal.

*p-value was analyzed by comparing the biopsy-proven FL patients with HT patients. Not applicable to c.*

The nodal mass (≥3 cm) was observed in only one nodal area. Not applicable to c.*

The nodal mass (≥7 cm) was observed in only one nodal area."
twice the upper limit of normal (ULN), focal LN enlargement (≥7 cm), and hypercalcemia at disease progression were observed only in patients with HT. More patients in the HT group had LDH elevation, hemoglobin <12 g/dl, C-reactive protein elevation, bulky disease, and focal LN enlargement (≥3 cm). On multivariate analysis, poor PS score, focal LN enlargement, LDH elevation, and hemoglobin <12 g/dl at disease progression were associated with HT (Table 2). We constructed the scoring system consisting of the aforementioned four factors; the weights of the variables were decided based on the regression coefficients. To assess the cutoff value that best distinguished HT from FL, we used the ROC curve analysis (Figure 2A). The area under the ROC curve (AUC) was high (0.91, 95% confidence interval [CI]: 0.828-0.981); the cutoff score was determined to be 3.31, which produced a high PPV (96.4%) and NPV (85.4%).

To develop a simple scoring system so as not to change the previous PPV/NPV, we assigned the scores with reference to the regression coefficients and the previous cutoff score (Table 2). Using the simplified transformation scoring system, TSS, the cutoff value was identified to be 2, which gave the same predictive value; the PPV and NPV were 96.4% and 85.4%, respectively (Figure 2B). According to the TSS score, the percentage of HT patients with scores of 0, 1, 2, 3, 4, and ≥5 were 5%, 33%, 91%, 100%, 100%, and 100%, respectively (Table 3 and Figure 3).

3.2 External validation set

As shown in Figure 1B (the NCCHE cohort), 243 patients were diagnosed with FL (grades 1, 2, or 3a) at the NCCHE with a median follow-up duration of 5.7 (range: 0.1-14.4) years. Disease progression was observed in 95 patients, of whom 50 (53%) had the histologic documentation (FL in 30 and HT with DLBCL in 20). Finally, we identified 50 patients with biopsy-proven FL or HT with DLBCL as subjects for the external validation analysis.

The clinical characteristics of 50 patients with biopsy-proven FL or HT at the time of disease progression are shown in Table S1. We applied the TSS to this completely independent cohort for external validation. Based on the ROC curve analysis, the AUC of the TSS in the external validation cohort was 0.900 (95% CI, 0.815-0.987) (Figure 2C). Furthermore, a score of 2 or higher produced a high PPV and NPV of 93.3% and 82.9%, respectively, for HT diagnosis, which confirmed the validity of the TSS. According to the TSS score, the percentage of patients with HT who had scores of 0, 1, 2, 3, 4, and ≥5 were 5%, 33%, 91%, 100%, 100% and 100%, respectively (Table 3 and Figure 3).

3.3 Outcomes and internal validation set

Among 459 patients with FL in the NCCH cohort, HT occurred at a median of 5.5 years (range, 0.2-16 years) after the initial FL diagnosis; the cumulative incidences of HT at 5 and 10 years were 4.2% (95% CI, 2.5-6.6) and 8.5% (95% CI, 5.6-12.1), respectively (Figure S1A). Among 243 patients with FL in the NCCHE cohort, HT occurred at a median of 5.3 years (range, 0.7-12.8 years) after the initial FL diagnosis, and the cumulative incidences of HT at 5 and 10 years were 5.0% (95% CI, 2.5-8.7) and 13.3% (95% CI, 7.7-20.3), respectively (Figure S1B).

Among 76 patients with biopsy-proven FL or HT in the derivation set, the probability of 5-year OS after disease progression was 96.9% (95% CI, 79.8-99.6) in patients with biopsy-proven FL and 62.2% (95% CI, 34.9-80.8) in patients with HT (p < 0.001; Figure 4A). Further, the probability of 5-year OS after disease progression was lower in patients with higher TSS scores (≥2) than in patients with lower scores (0-1) (58.9% [95% CI, 34.0-77.1] vs. 95.8% [95% CI, 73.9-99.4], p < 0.001; Figure 4B).

Furthermore, among the 459 patients with FL in the NCCCH cohort, 104 who developed disease progression could not undergo biopsy, including seven who were diagnosed with clinical transformation and treated accordingly. As an internal validation analysis, the TSS score distributions at first disease progression in these 104 patients are shown in Figure S1C and Table S2; 20 patients (19%) had a score of 2 or higher. Interestingly, the probability of 5-year OS after disease progression was lower in patients with higher scores than in patients with lower scores (63.4% [95% CI, 35.8-81.7] vs. 98.2% [95% CI, 88.0-99.7], p < 0.001; Figure 4C). Further, almost all the patients (86%) with higher TSS scores died of lymphoma, as shown in Table S2. Regarding the salvage therapies for the patients with higher scores, there were no statistically significant differences between this cohort and the derivation cohort, except with rituximab monotherapy (Table S3).
DISCUSSION

We developed and validated a new scoring system for determining the clinical transformation of FL, TSS, using two independent cohorts (the NCCH and NCCHE cohorts). It is difficult to obtain the specimen for biopsy in all patients with FL at the time of disease progression. In fact, the previous studies have indicated a low rate (20.6-42%) of performing biopsy at the time of disease progression of FL. Therefore, although histologic analysis is the gold standard for diagnosing transformation, our new scoring system will be useful for assessing the probability of transformation in patients who are unable to undergo the biopsy.

Diagnosing transformation is important for patients with FL because, despite the availability of rituximab, HT is still strongly associated with mortality in patients with FL. Therefore, although histologic analysis is the gold standard for diagnosing transformation, our new scoring system will be useful for assessing the probability of transformation in patients who are unable to undergo the biopsy.

Further, treatment strategies for patients with HT could be more intensive than those for patients without HT, and include procedures such as hematopoietic stem cell transplantation. Moreover, because the incidence of HT is one of the designated clinical trial endpoints of FL, reliable

**FIGURE 3** Probability of histologic transformation according to the transformation scoring system in the derivation and external validation sets. Abbreviation: HT, histologic transformation.
diagnosis of transformation is essential for assessing this endpoint accurately. However, there are many patients with FL who could not undergo a biopsy at the time of disease progression, even in clinical trials, which resulted in varying rates of transformation reported among such trials. Patients without biopsies are currently diagnosed with clinical transformation solely based on their clinical characteristics; however, because of the lack of standardized criteria for diagnosing the clinical transformation of FL, it has been difficult to compare the incidence rate of HT among the previously published studies.

Several studies have compared the clinical factors of FL and HT at the time of the initial diagnosis of FL to predict the risk of HT, including prospective cohort studies with a large number of patients. However, among available studies, the number of HT patients diagnosed by biopsy were limited, which resulted in varying HT risk factors and incidence rates being reported. On the contrary, although there have been a few studies that assessed the clinical factors at the time of disease progression in patients with HT, detailed comparisons between FL and HT have not been performed in the era of rituximab availability. Therefore, we elucidated the clinical factors associated with HT at the time of disease progression in the immunochemotherapy era.

A well-known criterion for clinical transformation has been derived from the Vancouver population-based analysis in the pre-rituximab era, wherein the clinical transformation was arbitrarily defined as exhibiting one or more of the five clinical manifestations including rapid nodal growth, extranodal sites, new B symptoms, LDH over twice the ULN, and new hypercalcemia. The reliability of this criterion was demonstrated by the close similarity in the clinical outcomes of patients diagnosed with clinical transformation using the criterion, to those diagnosed by biopsy. However, cohorts of patients with HT may be different in the pre- and post-rituximab eras, since the comparisons of these two periods have shown that the clinical outcomes of patients with HT were worse and the incidence of HT was higher in the pre-rituximab era. In addition, these five clinical factors were not verified using statistical models, although the impact of each of these factors on patients with HT is likely to be different. Thus, currently, there are no standardized criteria for diagnosing the clinical transformation of FL. In our study, we extracted the detailed clinical factors at the time of disease progression only from patients with biopsy-proven histology and performed statistical analyses, including the validation analysis, on these factors. This was in an attempt to standardize the definition of clinical transformation in the rituximab era. Furthermore, as one of the factors, “rapid nodal growth,” comprising the Vancouver criterion was not rigorously defined, it may be difficult to accurately use this criterion in

FIGURE 4 Kaplan-Meier curves showing overall survival according to histology and the transformation scoring system Probability of overall survival after disease progression in patients with FL vs. HT in the derivation set (A), overall survival after disease progression in patients with high vs. low TSS scores in the derivation set (B), and overall survival after disease progression in 104 patients who did not undergo biopsy at the first progression with high vs. low TSS scores in the internal validation set (C). Abbreviations: FL, follicular lymphoma; HT, histologic transformation; TSS, transformation scoring system
both daily practice and clinical trials. In contrast, the TSS, comprising of “focal LN enlargement,” was strictly defined and may indicate that only one nodal area progressed more rapidly than other nodal areas in patients with HT, which might better describe “rapid nodal growth.” Another possibility is that the persistence of one enlarged LN in FL patients may be associated with the development of HT. Therefore, the TSS can be evaluated quantitatively at a single time, thereby providing easy access to FL transformation in both daily practice and clinical trials.

As an internal validation analysis, we applied the TSS to 104 patients who did not undergo biopsy at the time of disease progression. Among them, the majority of patients (81%) had lower scores, according to the TSS. Importantly, the prognosis of the patients with higher scores (n = 20) was similar to that of patients with HT, although the salvage therapies among both cohorts were not the same. This might indicate that the TSS can be used to stratify FL patients with disease progression who did not undergo biopsy, and can diagnose them with the clinical transformation. Moreover, our new scoring system may be used as a prognostic index at the time of FL disease progression because among the 180 patients with disease progression in the NCCH cohort, the prognoses of patients with higher scores were poorer than that in the patients with lower scores, as shown in Figure 4B,C.

We also assessed the SUVmax value to distinguish HT patients from FL patients who underwent FDG-PET/CT (Supplementary material). In the both derivation and validation cohorts, a high SUVmax value indicated that patients with FL had developed HT, which was consistent with the previous studies. Although we tried to incorporate the SUVmax value into the TSS, a superior model could not be developed. Even in the cohort of patients who received PET/CT, the TSS was superior to the scoring system, which incorporated the SUVmax value in the derivation set (data not shown). Furthermore, the scoring system with the incorporated SUVmax value was not validated well because the SUVmax value in patients with HT in the external validation cohort was higher than that in the derivation cohort despite using similar PET/CT scanner, protocol, and software in the hospitals. Theoretically, the SUVmax value would vary among institutions because of the difference in PET/CT scanner and the method of SUV quantification. Thus, it is difficult to apply a certain SUVmax value to other institutions. In addition, because a recent study suggested that a high SUVmax value of the patients with FL at initial diagnosis was not associated with HT, an increase in SUVmax value at the time of disease progression compared to that at initial diagnosis may be important to assess HT. Owing to the aforementioned reasons, we did not incorporate the SUVmax value in the TSS.

This study has several limitations. First, due to the retrospective nature of this study, we analyzed limited number of patients who underwent a biopsy at the time of disease progression. This might have resulted in potential bias in developing the TSS, even though we validated it in a completely independent cohort. Second, the decision to perform a biopsy was at the physician’s discretion; however, the TSS was also validated in patients who did not undergo biopsy at the first progression. Third, as the TSS was developed to assess HT at the time of disease progression, it cannot predict HT in patients who were initially diagnosed with FL. Therefore, to confirm the TSS, prospective studies comprising a large number of patients may be warranted.

In conclusion, we developed a new scoring system for the clinical transformation of FL, TSS, and validated it in an independent cohort. The TSS promises to be a simple, yet, valuable tool, for the diagnosis of clinical transformation in both daily practice and clinical trials, especially in patients for whom obtaining a biopsy specimen is not feasible.

ACKNOWLEDGMENTS
This work was supported in part by a grant from the Japan Agency for Medical Research and Development (AMED) under Grant Numbers 17ck0106349h0001 and 18ck0106349h0002. The authors would like to thank the medical, nursing, data processing, laboratory, and clinical staff members at the participating centers for their important contributions to this study and their dedicated patient care.

CONFLICT OF INTEREST
DM has received research funding from Celgene, Chugai Pharmaceutical, Janssen Pharmaceutical, MSD, Mundipharma, Novartis Pharma, Ono Pharmaceutical, and Takeda Pharmaceutical and honoraria from Celgene, Chugai Pharmaceutical, Eisai, Janssen Pharmaceutical, Kyowa Kirin, Mundipharma, and Takeda Pharmaceutical. NY has received research funding from Amgen, Celgene, Ono Pharmaceutical, and paid expert testimony from Takeda Pharmaceutical. KI has received research funding from AbbVie, AstraZeneca, Bayer Pharma, Celgene, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, HUYA Japan, Kyowa Kirin, Incyte, Janssen Pharmaceutical, Novartis Pharma, Ono Pharmaceutical, Pfizer, Sanofi, Solasia Pharma, Symbio, Takeda Pharmaceutical, Yakult, and Zenyaku Kogyo, and honoraria from Eisai, and Kyowa Kirin. KeT has received honoraria from Celgene, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, HUYA Bioscience International, Kyowa Kirin, Mundipharma, Ono Pharmaceutical, Takeda Pharmaceutical, Yakult, and Zenyaku Kogyo. All other authors declare no conflict of interest.

AUTHORS’ CONTRIBUTIONS
Conception and design: Takafumi Shichijo, Dai Maruyama Provision of study materials or patients: All authors Collection
and assembly of data: Takafumi Shichijo, Nobuhiko Yamauchi, Sayako Yuda, Akiko Miyagi Maeshima, Masato Sugano, Hiroaki Kurihara, Kaoru Shimada, Dai Maruyama Data analysis and interpretation: Takafumi Shichijo, Dai Maruyama, Kinuko Tajima, Koji Izutsu, Kensei Tobinai Manuscript writing: Takafumi Shichijo, Dai Maruyama Final approval of manuscript: All authors

DATA AVAILABILITY STATEMENT
Inquiries for data should be directed to dmaruyama@ncc.go.jp. The date will be available for achieving aims in the approved proposal.

ORCID
Takafumi Shichijo https://orcid.org/0000-0002-1272-3738
Dai Maruyama https://orcid.org/0000-0003-2378-7865
Kosuke Toyoda https://orcid.org/0000-0001-8125-4528
Shinichi Makita https://orcid.org/0000-0001-6609-8088
Yukio Kobayashi https://orcid.org/0000-0003-2378-7865

REFERENCES
1. Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2019;95:316–327.
2. Carbone A, Roulland S, Gloghini A, et al. Follicular lymphoma. Nature Rev Dis Primers. 2019;5:83.
3. Ardesha KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin's lymphoma: a randomised controlled trial. Lancet. 2003;362:516–522.
4. Solal-Céligny P, Beller M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30:3848–3853.
5. Yuda S, Maruyama D, Maeshima AM, et al. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era. Ann Hematol. 2016;95:2017–2022.
6. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732.
7. Herold M, Haas A, Strock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986–1992.
8. Marcus R, Imrie K, Solal-Céligny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579–4586.
9. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112:4824–4831.
10. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet. 2011;377:42–51.
11. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1–2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122:981–987.
12. Watanabe T, Tobinai K, Shibata T, et al. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol. 2011;29:3990–3998.
13. Watanabe T, Tobinai K, Wakabayashi M, et al. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol. 2018;5:e520–e531.
14. Maeshima AM, Taniguchi H, Fukuhura S, et al. Clinicopathological prognostic indicators in 107 patients with diffuse large B-cell lymphoma transformed from follicular lymphoma. Cancer Sci. 2013;104:952–957.
15. Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126:851–857.
16. Sarkozy C, Trenery M, Xerri L, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34:2575–2582.
17. Alonso-Álvarez S, Magnano L, Alcoceba M, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017;178:699–708.
18. Janikova A, Bortliecz Z, Campr V, et al. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. Ann Hematol. 2018;97:669–678.
19. Cm S, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: A pooled analysis of French and US cohorts. J Clin Oncol. 2019;37:144–152.
20. Al-Tourah AJ, Sehn LH, Moccia AA, et al. Transformation of follicular lymphoma in the era of immuno-chemotherapy: a population-based study from British Columbia. J Clin Oncol. 2012;30(15 Suppl):8049.
21. Federico M, Barrigón MD, Marcheselli L, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5:e359–e367.
22. Bastiont Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15:1587–1594.
23. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426–2433.
24. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:5165–5169.
25. Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157:188–196.
26. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy...
era: A report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31:3272–3278.

27. Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood. 2015;125:40–47.

28. Luminari S, Ferrari A, Manni M, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018;36:689–696.

29. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon, France: IARC Press; 2008.

30. Jaffe ES. The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009;2009:523–531.

31. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.

32. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458.

33. Villa D, Crump M, Panzarella T, et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol. 2013;31:1164–1171.

34. Madsen C, Pedersen MB, Vase MØ, et al. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. Ann Oncol. 2015;26:393–399.

35. van-Hoeven M, Vanderplas A, Crosby-Thompson AL, et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol. 2013;163:487–495.

36. Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:4643–4651.

37. Bodet-Milin C, Knebel-Bodéré F, Moreau P, et al. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica. 2008;93:471–472.

38. Noy A, Schöder H, Gönen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20:508–512.

39. Wondergem MJ, Rizvi SN, Jauw Y, et al. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma. J Nucl Med. 2015;56:216–221.

40. Farheen M, Sally FB, Helen B, et al. Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. Blood. 2020;135:1214–1218.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

[Correction added on 22 October 2020, after first online publication: In Supplementary Table S3, the authors would like to change the drug name “Ofatumumab momotherapy” and “Polatuzumab vedptin” to “Others” because these agents are not approved for relapsed FL/DLBCL in Japan.]

How to cite this article: Shichijo T, Maruyama D, Yamauchi N, et al. Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma. Cancer Med. 2020;9:8864–8874. https://doi.org/10.1002/cam4.3501